Background: In the Post Exposure Prophylaxis of Infants (PEPI)-Malawi trial, infants received up to 14 weeks of extended nevirapine (NVP) or extended NVP with zidovudine (NVP þ ZDV) to prevent postnatal HIV transmission. We examined emergence and persistence of NVP resistance in HIV-infected infants who received these regimens prior to HIV diagnosis.
Introduction
Strategies to prevent postnatal HIV transmission are important when breastfeeding is critical to infant health and survival. In these settings, extended daily infant nevirapine (NVP) reduces the risk of postnatal motherto-child transmission of HIV compared with single-dose NVP (sdNVP) alone [1] or sdNVP along with a short tail of other antiretroviral drugs [2, 3] , and is one option recommended by the WHO for prevention of postnatal HIV transmission [4] . Unfortunately, NVP-resistant HIV frequently emerges in HIV-infected infants who receive sdNVP prior to HIV diagnosis [5] [6] [7] [8] . NVP resistance emerges more frequently after exposure to extended NVP prophylaxis [9] [10] [11] [12] . Prior exposure to sdNVP can compromise the response of HIV-infected infants to nonnucleoside reverse transcriptase inhibitor (NNRTI)containing treatment regimens [13, 14] . For this reason, the WHO currently recommends use of protease inhibitor-based regimens rather than NNRTI-based regimens to treat NVP-exposed, HIV-infected infants [15] . Unfortunately, protease inhibitors are not widely available in many resource-limited settings and are more costly than NNRTIs. One approach to address the limited availability and higher cost of protease inhibitorcontaining regimens is to initiate treatment of NVPexposed, HIV-infected infants with protease inhibitorcontaining regimens and subsequently switch them to NNRTI-containing regimens [16] . It is not known whether this strategy would also be effective in HIVinfected infants who were exposed to extended NVP prophylaxis prior to HIV diagnosis.
Studies from our group and others have shown that NVPresistant HIV can persist for a year or more in infants after sdNVP exposure [5, 6, 17] . Persistence of NVP-resistant HIV appears to be more pronounced after exposure to extended NVP prophylaxis [9] [10] [11] . In the Six-Week Extended Nevirapine (SWEN) trial, infants in Uganda, India, and Ethiopia received either sdNVP or extended NVP prophylaxis up to 6 weeks of age [1] . Among HIVinfected Ugandan infants who had NVP resistance at 6 weeks of age, NVP-resistant HIV variants were still detected at 6 months in all seven evaluable infants who received the extended NVP regimen, compared with only one of six infants who received sdNVP alone [9] . NVP-resistant strains were also detected in Indian infants [10] and in Ethiopian infants in the SWEN trial [11] at 6-7 months of age.
In this report, we analyzed emergence and persistence of NVP resistance among infants who received up to 14 weeks of extended NVP prophylaxis in the Post Exposure Prophylaxis of Infants (PEPI)-Malawi trial (#NCT00115648) [2] . In PEPI-Malawi, women who presented early in labor received sdNVP; those who presented less than 4 h prior to anticipated delivery (too late for HIV testing, counseling, and sdNVP administration prior to delivery) did not receive sdNVP. Infants were randomized at birth to one of three study arms: sdNVP with 1 week of daily zidovudine (ZDV) (control), control with daily NVP up to 14 weeks of age (extended NVP), or control with daily NVP and ZDV up to 14 weeks of age (extended NVP þ ZDV). We previously analyzed NVP resistance in infants in the extended study arms of PEPI-Malawi who were HIV-infected in utero [12] . In those infants the addition of extended ZDV to extended NVP prophylaxis significantly reduced the frequency of NVP resistance at 14 weeks of age from 86.0% (37/43) to 62.2% (28/45), P ¼ 0.015 [12] . This report extends our previous report by analyzing HIV drug resistance in all infants in the extended study arms who were diagnosed with HIV infection by 14 weeks of age. This report also includes analysis of the persistence of NVP-resistant HIV in infants up to 1 year old.
Methods
Samples used for analysis Samples and data were obtained from the PEPI-Malawi trial [2] . Prophylaxis was stopped in HIV-infected infants following confirmation of an initial positive HIV-DNA PCR test. Infant plasma was stored at birth, 3, 6, 9, and 14 weeks, and 6, 9, 12, 18, and 24 months of age. In November 2008, 220 infants in the extended study arms were identified who were HIV-infected by 14 weeks of age (106 in the extended NVP arm, 114 in the extended NVP þ ZDV arm); this included infants who were HIVinfected in utero, who were not included in the primary analysis of the PEPI-Malawi trial [2] . Infants were excluded from analysis if their mothers started antiretroviral treatment (all women who were excluded because of antiretroviral treatment initiation received NVP/lamivudine/stavudine). The 108 infants included in the analysis in this report included 79 infants described in a previous study [12] ; that study was limited to analysis samples collected at 14 weeks of age and used a single method for analysis of NVP resistance (the ViroSeq system, see below).
Laboratory methods
Infant plasma samples collected at 14 weeks of age were analyzed using the ViroSeq HIV Genotyping System (Celera, Alameda, California, USA); 25-100 ml was used for analysis. The ViroSeq system is a population sequencing-based assay that provides information about mutations in HIV protease (amino acids 1-99) and HIV reverse transcriptase (amino acids 1-335). Samples collected at 14 weeks, 6, and 12 months of age were analyzed using the LigAmp assay [18] to detect the K103N mutation (assay cutoff: 0.5% K103N) and the Y181C mutation (assay cutoff: 1% Y181C). The LigAmp assay is a sensitive, quantitative point mutation assay that can be used to detect specific drug resistance mutations in HIV. LigAmp was performed as described [9] using primers designed for subtype C HIV. tests for resistance in the same infants. Statistical significance was considered for two-sided P-value of 0.05 or less. All analyses were performed using SAS Software Version 9.1 (SAS Institute Inc., Cary, North Carolina, USA).
Statistical analysis

Ethical considerations
Written informed consent for participation in the PEPI-Malawi trial was obtained from all the women. The study was approved by Institutional Review Boards (IRB) in Malawi and the USA as described elsewhere [2] , including the US Centers for Disease Control and Prevention IRB.
Results
Plasma samples collected at 14 weeks of age were available for 151 (68.6%) of the 220 HIV-infected infants who received either extended NVP or extended NVP þ ZDV prophylaxis in PEPI-Malawi. Sixty-nine infants did not have a 14-week sample available for testing (36 samples were used up in previous testing, the parents of 16 infants refused to participate in the trial after enrollment, 10 infants died, four infants were lost to follow-up, one infant missed the 14-week study visit, one infant relocated, and one infant's sample could not be located); four of the 151 available 14-week samples were not tested because the mother initiated antiretroviral treatment prior to the 14week study visit. Resistance test results (ViroSeq and LigAmp, see methods section) were obtained for 108 (73.5%) of the 147 samples that were tested (53 in the extended NVP arm, 55 in the extended NVP þ ZDVarm); 39 samples failed analysis (no amplification). Table 1 shows characteristics of the 108 infants who had resistance test results (included in the substudy) and of the 112 infants who did not. There were no statistically significant differences in these two groups of infants for the following variables: the proportion of infants in the extended NVP vs. extended NVP þ ZDV study arms, the duration of prophylaxis received prior to HIV diagnosis, the median maternal CD4 cell count at study enrollment, the proportion of infants whose mothers received sdNVP, or the proportion of infants with in utero HIV infection. The median maternal HIV log 10 viral load at enrollment was lower for infants included in this substudy ( Table 1) . Fig. 1a ). We also did not find a significant association between detection of NVP resistance at 14 weeks of age using the LigAmp assay and any of the clinical or laboratory variables described above (Table 1) .
We next used the LigAmp assay to analyze persistence of K103N and Y181C in infants who had those mutations detected at 14 weeks of age. Sixty-eight (87.2%) of the 78 infants who had NVP resistance at 14 weeks of age were still alive at 6 months; 55 of those 68 infants had a 6-month sample available for analysis (13 samples were Median and interquartile range are shown. Data for the duration of prophylaxis were not available for one infant included in the study who did not have resistance, and 18 infants who were not included in the study. Maternal HIV viral load data were not available for eight infants included in the study (five who had resistance, three who did not) and 10 infants who were not included in the study. CD4 cell count data were not available for 25 infants included in the study (20 who had resistance, five who did not) and 34 infants who were not included in the study. used up in other testing). Three of the 55 samples were not included in the analysis because the mother started antiretroviral treatment before the 6-month visit and six samples failed analysis (no amplification). The remaining 46 samples were analyzed. Thirty-eight (82.6%) of the 46 infants still had K103N and/or Y181C detected at 6 months of age. There was no significant difference in detection of these mutations in the two study arms (P ¼ 1.0, Fisher's exact test, Fig. 1b ). Five infants had NVP resistance mutations other than K103N and Y181C detected by ViroSeq at 14 weeks (V106A, Y188C/L, and G190A) in the absence of K103N or Y181C. Four of the five infants had a 6-month sample available for analysis with ViroSeq. Three of the four infants did not have any NVP resistance mutations detected in the 6-month sample; in one infant, G190A was detected.
A similar analysis was performed to analyze persistence of NVP resistance at 12 months of age. Twenty-six (68.4%) of the 38 infants who had NVP resistance at 6 months of age were still alive at 12 months; 21 of those 26 infants had a 12-month sample available for analysis (four samples were used up in previous testing, one infant relocated). Two of the 21 samples were not included in the analysis because antiretroviral treatment was initiated before the 12-month visit in both of the mothers and in one of the infants. We also analyzed 12-month samples from infants who had NVP resistance detected at 14 weeks, but did not have a 6-month sample available for analysis. Among 19 infants in that group, 14 were still alive at 12 months and 10 of those were evaluable (one infant relocated, the parents of one infant refused further participation in the trial, one infant missed the 12-month study visit, and one mother started antiretroviral treatment before the 12-month visit). Therefore, a total of 29 12-month samples were tested (19 samples from infants who had resistance detected at 6 months of age and 10 samples from infants who had resistance detected at 14 weeks of age who did not have a resistance testing result from the 6-month visit). Nineteen (66.5%) of the 29 infants who were included in the analysis still had K103N and/or Y181C detected at 12 months of age (Fig. 1b ). There was no significant difference in the percentage of infants in the extended NVP vs. extended NVP þ ZDV study arms who had detectable K103N or Y181C at either 6 or 12 months (P ¼ 1.0 at 6 months, P ¼ 0.43 at 12 months, Fisher's exact test, Fig. 1b ). The LigAmp assay provides a quantitative measure of the percentage of the viral population in a sample that has the mutation of interest. There was no significant difference in the level of K103N or Y181C detected in the infants in these two groups at the 6-month or 12-month visits (data not shown). 
Discussion
This study first analyzed the frequency of NVP resistance in 14-week-old HIV-infected infants who received either extended NVP or extended NVP þ ZDV prophylaxis prior to HIV diagnosis. Initiation of antiretroviral treatment within the first 3 months of life is associated with a dramatic reduction in infant mortality [19] . The presence of detectable NVP resistance at 14 weeks of age may compromise the infant's response to antiretroviral treatment initiated in the first 3 months of life. In PEPI-Malawi, most (82/108 ¼ 75.9%) HIV-infected infants who received extended NVP or extended NVP þ ZDV prophylaxis prior to HIV diagnosis (including those with in utero infection) had detectable NVP resistance at 14 weeks of age.
In our previous analysis of infants in PEPI-Malawi who had in utero HIV infection, NVP resistance was significantly less frequent at 14 weeks of age in the extended NVP þ ZDV arm than in the extended NVP arm (62.2 vs. 86.0%, P ¼ 0.015) [12] . In this larger study, which included all evaluable infants who were diagnosed with HIV infection by 14 weeks of age, the same trend was observed (i.e., the frequency of NVP resistance was lower at 14 weeks in infants who received extended NVP þ ZDV than among those who received extended NVP alone), but the difference was not statistically significant (69.1 vs. 83.0%, P ¼ 0.12). We did not identify any clinical or laboratory factors associated with emergence of NVP resistance at 14 weeks of age; factors analyzed included duration of prophylaxis (infant age when prophylaxis was stopped), maternal viral load or CD4 cell count at study enrollment, maternal sdNVP exposure, and timing of infant HIV infection [diagnosis of HIV infection (in utero infection) at vs. after delivery]. Most often, infants who had NVP resistance at 14 weeks of age had at least one NVP resistance mutation that was present at a sufficient level for detection using a population sequencing-based genotyping assay (ViroSeq). However, there was no statistically significant difference in the frequency of NVP resistance mutations using ViroSeq or a sensitive point mutation assay (LigAmp) at that study visit.
We also analyzed the persistence of NVP-resistant variants among infants who had NVP resistance detected at 14 weeks of age. The NVP resistance mutations, K103 and Y181C, were still detectable in 82.6% of evaluable infants at 6 months of age and in 65.5% of evaluable infants at 12 months of age. Five infants had other NVP resistance mutations detected at 14 weeks of age in the absence of K103N or Y181C (V106A, Y188C/L, and G190A). Those mutations are associated with high-level NVP resistance, with variable levels of resistance to other NNRTIs [20]. We did not analyze persistence of those mutations in this study. However, a previous study suggests that some of those mutations (V106M, Y188C, and G190A) may be less likely to persist at high levels in infants after NVP exposure than K103N and Y181C [11] . The frequent persistence of the K103N and Y181C mutations in infants after exposure to extended NVP prophylaxis prior to HIV diagnosis, with or without concomitant ZDV, suggests that exposure to these regimens may compromise an infant's subsequent response to an NNRTI-based treatment regimen, even if treatment initiation is delayed until 6-12 months of age. However, clinical trials are needed to evaluate the efficacy of different treatment strategies in infants who were exposed to these regimens prior to HIV diagnosis.
It is important to note that all of the infants described in this report had subtype C HIV infection. Our previous studies demonstrated that both women and infants with subtype C HIV are more likely to develop NVP resistance after sdNVP exposure than those infected with other HIV subtypes (A or D HIV) [7, 21] . In women, NVP resistance also tends to persist longer after sdNVP in some subtypes (e.g., longer in subtype D vs. A) [22] . Further studies are needed to evaluate persistence of NVP resistance in infants exposed to extended NVP prophylaxis who are infected with different HIV subtypes and to evaluate whether HIV subtype influences the subsequent response of those infants to NNRTI-based treatment regimens, with or without initial treatment with a protease inhibitor-based regimen.
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